Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pre-hospital Care With Intra-Nasal Ketamine for Transport (PRECINKT): A Pilot Study (PRECINKT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02033434
Recruitment Status : Completed
First Posted : January 10, 2014
Last Update Posted : September 26, 2019
Sponsor:
Collaborator:
University of British Columbia
Information provided by (Responsible Party):
Dr. Greg Haljan, University of Calgary

Brief Summary:

The investigators hypothesize that intra-nasal ketamine, for analgesia of patients with moderate to severe pain in an alpine setting, will provide a clinically significant reduction in pain and provide an effective and feasible alternative to intravenous opioids.

The investigators wish to know:

  1. Is our study protocol feasible to study INK in a mountain, prehospital care environment?
  2. What estimate can be made of recruitment rates?
  3. Does studying the use of INK interfere with or delay care at Whistler/Blackcomb?
  4. Is intra-nasal ketamine an effective and safe method for controlling pain in our study population and setting?
  5. Does intranasal ketamine provide a clinically significant reduction in pain or do patients require additional IV narcotics for extraction?
  6. Are there any significant changes in vital signs after administration of intra-nasal ketamine
  7. Does the use of intra-nasal ketamine reduce time of patient extraction and transport in the alpine pre-hospital setting?
  8. Are there any long term sequelae of INK at one week?

Condition or disease Intervention/treatment Phase
Pain Traumatic Limb Injury Drug: Intranasal Ketamine Phase 1

Detailed Description:

Whistler/Blackcomb is a large world-class resort that attracts hundreds of thousands of skiers and snowboarders annually for it's steep terrain and excellent on-mountain facilities. Ski patrol operations exist on both mountains and respond to over 10000 injuries per year (1). As both skiing and snowboarding activities gain popularity, the number of people injured also rises (2) as does the demand on ski patrol and attending on-mountain physicians to provide adequate on-mountain treatment.

The provision of analgesia, both to relieve patient suffering and facilitate transport, is a central tenet of pre-hospital care. This is of special import in an alpine setting where environmental factors and challenges with extrication play a significant role in patient outcomes (3). Despite its significance to both patient and practitioner, adequate and timely pain relief is often delayed. The underlying cause is multifactorial; intravenous access is challenging, there is limited availability of advanced health care providers and monitoring capabilities. To date, there remain no widespread guidelines for treatment of acute pain in alpine rescue and ski patrol setting.

Intravenous (IV) opioid analgesia is widely used as a primary method of attaining pain control. While effective, this route of administration has several shortcomings. The insertion of an IV is invasive, painful,, time-consuming, exposes skin to cold injury and delays transport. Opioids also raise the risk of hypotension, hypoxemia and vomiting. In previous work (15), the intranasal (IN) route of medication delivery is rapid, effective and well-tolerated. In addition adverse side effects are minor and transient, and there are no changes in vital signs that required clinical intervention.

This data corroborated previous research that low dose ketamine provides safe and meaningful analgesia while preserving cardiovascular function, respiratory drive and airway reflexes (27). Thus, the use of IN ketamine reduces the need for IV access in stable patients and and reduces the need for monitoring to the risks of opioids (6). These characteristics indicate great potential for ketamine in reducing the extraction and transport time of patients from the mountain environment.

Intranasal ketamine is very attractive in austere and alpine environments, where monitoring capabilities slow transport and IV access is difficult. Previous case reports suggest that IN ketamine provides a rapid, easily administered and effective method of analgesia in the pre-hospital setting (7). However, there is no data on the feasibility of conducting a medical trial in a large busy commercial ski area, nor to calculate an appropriate sample size. The investigators propose a pilot study to investigate the feasibility of conducting a study of IN ketamine (INK) prior to a larger study to determine if INK provides an effective and safe method of analgesia for patients presenting to ski patrol with acute injuries. In addition, although the current body of literature shows minimal adverse events, the investigators will continue to study the safety of INK and monitor for any negative side effects. The purpose is to provide insight and information on the potential utility of IN ketamine in this setting, and to assess feasibility of future clinical trials powered to demonstrate efficacy and safety.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pre-hospital Care With Intra-Nasal Ketamine for Transport (PRECINKT): A Pilot Study
Actual Study Start Date : March 1, 2014
Actual Primary Completion Date : May 15, 2016
Actual Study Completion Date : September 1, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Ketamine

Arm Intervention/treatment
Experimental: Intranasal Ketamine
All patients
Drug: Intranasal Ketamine
Atomized Intranasal Ketamine, 50mg




Primary Outcome Measures :
  1. analgesia [ Time Frame: 30 minutes ]
    clinical effect of intranasal ketamine on pain score measured by verbal analogue scale


Secondary Outcome Measures :
  1. transport time [ Time Frame: 60 minutes ]
    the transport time from arrival of first responder to arrival at ambulance pick-up will be compared to historical controls.

  2. cardiorespiratory stability [ Time Frame: 30 minutes ]
    effect of ketamine on heart rate, blood pressure, respiratory rate and oxygen saturation

  3. Satisfaction with medical care and evacuation [ Time Frame: 1 week ]
    Patient, first responder and clinician satisfaction with study protocol and analgesia



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • traumatic extremity injury
  • age greater than 18 years old
  • moderate or severe pain (VNRS 5 or greater)

Exclusion Criteria:

  • need for an intravenous catheter as judged by treating physician
  • pregnancy
  • unable to speak English
  • shoulder dislocations,
  • previous hypersensitivity, intolerance, or allergy to ketamine,
  • structural or functional nasal occlusion,
  • inability to understand the VNRS,
  • Glasgow Coma Scale <15,
  • inability to give informed consent
  • history of schizophrenia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02033434


Locations
Layout table for location information
Canada, British Columbia
Whistler Blackcomb
Whistler, British Columbia, Canada, V0N 1B4
Sponsors and Collaborators
University of Calgary
University of British Columbia
Investigators
Layout table for investigator information
Principal Investigator: Gary Andolfatto, MD University of British Columbia

Layout table for additonal information
Responsible Party: Dr. Greg Haljan, Co-principal Investigator, University of Calgary
ClinicalTrials.gov Identifier: NCT02033434    
Other Study ID Numbers: PRECINKT-001
First Posted: January 10, 2014    Key Record Dates
Last Update Posted: September 26, 2019
Last Verified: September 2019
Keywords provided by Dr. Greg Haljan, University of Calgary:
intranasal
ketamine
analgesia
mountain medicine
pre-hospital care
patient transport
pilot study
mountain environment
Additional relevant MeSH terms:
Layout table for MeSH terms
Ketamine
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action